As others mentioned, some warrants are being exercised which will help with financing. How much this has brought in is unknown, but any cash is better than none as this is non-dilutive (or at least limited dilution if any incentive received).

I expect a TO before any further RDO rounds are offered. Personally, I think with a TO, milestone payments, and potential license deal for non-US HIV, NASH, etc. that they will raise enough to avoid any significant dilution......I'll stand by this theory unless they request an increase to the authorized shares above 700M as they don't have a whole lot of shares available unless they pay noteholder off to free up ~40M shares reserved for conversion. This would obviously require cash to do so, but I would hope that they can get better funding than continuing to let the noteholder drive down our share price and dilute us by receiving monthly payments based on $.50 conversion price.....I would prefer a loyal shareholder to receive $.50+ shares than the slimy noteholder.